Doctors Note Logo

Published on: 3/12/2026

Still Flaring? Why Your Gut Is Resisting Meds and New JAK Inhibitors for UC Next Steps

There are several factors to consider if your UC is still flaring despite treatment, including a poor medication fit, secondary loss of response, persistent inflammation, or non-UC causes like infection or IBS overlap. Next steps often include objective reassessment and either optimizing current therapy or switching classes, including discussing oral JAK inhibitors for UC such as tofacitinib or upadacitinib with appropriate screening and monitoring.

Key safety considerations, red flag symptoms, and guidance on tests, drug levels, clinical trials, and when surgery is appropriate are detailed below, which can significantly influence the best path forward with your care team.

answer background

Explanation

Still Flaring? Why Your Gut Is Resisting Meds — and New JAK Inhibitors for UC as Next Steps

If you're living with ulcerative colitis (UC) and still flaring despite treatment, you're not alone. Many people with UC go through periods where medications seem to lose effectiveness or never fully control symptoms in the first place.

Ongoing diarrhea, urgency, blood in the stool, abdominal pain, and fatigue can be frustrating and exhausting. The good news is that treatment options have expanded significantly in recent years — including newer JAK inhibitors for UC, which may offer another path forward when other medications haven't worked.

Let's break down why your gut may be "resisting" treatment and what your next steps could be.


Why Am I Still Flaring on Medication?

There are several medically recognized reasons UC symptoms can persist despite treatment.

1. The Medication May Not Be the Right Fit

Ulcerative colitis is not a one-size-fits-all disease. It varies in:

  • Severity (mild, moderate, severe)
  • Extent (proctitis vs. left-sided vs. pancolitis)
  • Immune system activity
  • Individual response to medication

Common UC treatments include:

  • 5-ASA medications (mesalamine)
  • Corticosteroids
  • Immunomodulators (azathioprine, 6-MP)
  • Biologic therapies (anti-TNF agents, vedolizumab, ustekinumab)
  • JAK inhibitors for UC

If inflammation remains active, it may mean your current medication isn't strong enough — or isn't targeting the right inflammatory pathway.


2. Loss of Response Over Time

Even if a medication worked before, it may stop working. This is called secondary loss of response.

This can happen because:

  • Your immune system develops antibodies against a biologic drug.
  • Drug levels drop too low.
  • Inflammation pathways shift.

In these cases, your doctor may:

  • Adjust the dose
  • Shorten the dosing interval
  • Switch to a different class of medication

3. Inflammation Is Still Active (Even If Symptoms Fluctuate)

Symptoms can come and go, but inflammation may still be damaging your colon lining. Ongoing inflammation increases the risk of:

  • Severe flares
  • Hospitalization
  • Colon damage
  • Long-term complications

This is why doctors aim for more than symptom relief — they aim for mucosal healing (healing of the colon lining seen on colonoscopy).


4. It May Not Be Just UC

Sometimes worsening symptoms are caused by:

  • Infections (like C. diff)
  • Irritable bowel syndrome overlapping with UC
  • Medication side effects
  • Stress or sleep disruption

That's why reassessment is important if symptoms change.

If you're experiencing new or worsening symptoms and want to better understand what might be going on before your next appointment, consider using a free Ulcerative Colitis symptom checker to help organize and evaluate what you're feeling.


When Standard Treatments Aren't Enough: Enter JAK Inhibitors for UC

If you've failed or lost response to conventional therapies or biologics, your doctor may discuss JAK inhibitors for UC as a next step.

What Are JAK Inhibitors?

JAK inhibitors (Janus kinase inhibitors) are oral medications that block specific enzymes inside immune cells. These enzymes are part of the signaling system that drives inflammation in ulcerative colitis.

Instead of targeting a single inflammatory molecule (like some biologics do), JAK inhibitors work inside the immune cell, interrupting multiple inflammatory signals at once.

Currently approved JAK inhibitors for UC include:

  • Tofacitinib
  • Upadacitinib

These medications are supported by large clinical trials and are approved for moderate to severe ulcerative colitis.


Why JAK Inhibitors for UC Can Be Effective

Clinical studies show that JAK inhibitors can:

  • Reduce rectal bleeding
  • Decrease stool frequency
  • Induce remission
  • Promote mucosal healing
  • Work quickly (sometimes within weeks)

They are particularly useful for people who:

  • Failed anti-TNF biologics
  • Lost response to other biologics
  • Prefer an oral medication over injections or infusions

For many patients, the speed of symptom relief is one of the most meaningful benefits.


Are JAK Inhibitors Safe?

Like all immune-modifying medications, JAK inhibitors for UC carry potential risks. It's important to be informed — not alarmed.

Possible risks include:

  • Increased risk of infections (including shingles)
  • Blood clots (rare but serious)
  • Elevated cholesterol levels
  • Liver enzyme changes

Because of these risks, doctors:

  • Screen for infections before starting treatment
  • Monitor blood work regularly
  • Carefully assess cardiovascular and clotting risk factors

For many patients, the benefits outweigh the risks — especially when UC remains uncontrolled. The key is individualized decision-making with your gastroenterologist.


Other Next Steps If You're Still Flaring

If symptoms persist, your doctor may recommend:

✅ Re-evaluating Disease Activity

  • Colonoscopy or sigmoidoscopy
  • Stool inflammation markers (like fecal calprotectin)
  • Blood tests

✅ Optimizing Current Therapy

  • Adjusting doses
  • Combination therapy
  • Checking drug levels

✅ Switching Drug Classes

Moving from:

  • Anti-TNF → integrin blocker
  • Biologic → JAK inhibitors for UC
  • Or vice versa

✅ Considering Clinical Trials

There are ongoing studies investigating new oral agents and biologics.

✅ Surgery (When Necessary)

In severe, treatment-resistant cases, surgery to remove the colon may be recommended. While this can sound overwhelming, it can also be life-changing for patients with uncontrolled disease.


Don't Ignore Red Flag Symptoms

While most flares are manageable, seek urgent medical care if you experience:

  • Severe abdominal pain
  • High fever
  • Rapid heart rate
  • Severe dehydration
  • Continuous heavy rectal bleeding
  • Signs of blood clots (leg swelling, chest pain, shortness of breath)

These situations can be serious or life-threatening. Speak to a doctor immediately if any of these occur.


A Balanced Perspective: Hope Without False Promises

It's important to be realistic.

Not every medication works for every person. Finding the right therapy can take time. But the treatment landscape for ulcerative colitis has improved dramatically in the last decade.

JAK inhibitors for UC represent a major advance, especially for patients who previously had limited options after biologic failure.

The goal today is not just symptom control — it's sustained remission and prevention of long-term damage.


What You Can Do Now

If you're still flaring:

  • Track your symptoms.
  • Don't assume "this is just how UC is."
  • Ask about objective testing to measure inflammation.
  • Discuss whether JAK inhibitors for UC are appropriate for you.
  • Review your cardiovascular and infection risk profile with your doctor.

If you need help identifying whether your current symptoms align with active Ulcerative Colitis or something else, a quick online symptom assessment can give you clarity and confidence heading into your next doctor's visit.


Final Thoughts

Persistent flares don't mean you've failed. And they don't mean your condition is hopeless.

They usually mean your treatment plan needs adjusting.

With modern therapies — including JAK inhibitors for UC — many patients who once struggled to find relief are now achieving remission.

But ulcerative colitis is a serious inflammatory disease. Never ignore severe symptoms, and always speak to a doctor about anything that could be life-threatening or worsening.

The right treatment may not be the first one you try — but it may be the next one.

(References)

  • * Al-Sadi, H., & Al-Zoubi, M. M. (2022). Management of Refractory Ulcerative Colitis: A Comprehensive Review. Inflammatory Bowel Diseases, 28(10), 1546-1558.

  • * Danese, S., & Peyrin-Biroulet, L. (2022). Optimizing the use of JAK inhibitors in ulcerative colitis. Lancet Gastroenterology & Hepatology, 7(12), 1163-1175.

  • * Sandborn, W. J., & Feagan, B. G. (2023). Advances in the management of ulcerative colitis: Current and emerging therapies. Lancet Gastroenterology & Hepatology, 8(1), 77-89.

  • * Ungaro, R., & Colombel, J. F. (2020). Mechanisms of resistance to biologic therapies in inflammatory bowel disease. Gastroenterology, 159(3), 774-789.

  • * Regueiro, M., & Dulai, P. S. (2023). Stratifying Patients With Ulcerative Colitis to Optimize Treatment Response: Personalized Medicine in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 21(1), 22-30.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Learn more about diseases

Ulcerative Colitis

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.